Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation.
Source check: Source checked. Not independent scientific confirmation.
Finding: ML and structure-based pharmacophore screening identify JAK1 inhibitor candidates; four purchasable compounds were bio-evaluated and Z-10 showed kinase inhibition (IC50 194.9 nM). Experimental biochemical validation supports a specific inhibitor candidate; no therapeutic efficacy is claimed. AI role: Machine-learning classifiers with pharmacophore screening. The article appeared in Journal Of Translational Medicine.
Technology: Machine-learning classifiers with pharmacophore screening
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Machine-learning classifiers with pharmacophore screening
- Test and result
- ML and structure-based pharmacophore screening identify JAK1 inhibitor candidates; four purchasable compounds were bio-evaluated and Z-10 showed kinase inhibition (IC50 194.9 nM). Experimental biochemical validation supports a specific inhibitor candidate; no therapeutic efficacy is claimed.
- Limitation / still unknown
- The result is limited to the described dataset, cohort, experimental system, or validation design; generalization beyond that scope and downstream real-world benefit are not established. Author affiliation was not stated in the reviewed abstract or metadata.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://link.springer.com/article/10.1186/s12967-023-04443-6 · https://pubmed.ncbi.nlm.nih.gov/37641144/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.